Zoledronic acid (ZOL) is a potent amino-bisphosphonate used for the treatment of bone metastases with recently reported antitumor activity. However, the short plasma half-life and rapid accumulation in bone limits the use of ZOL as an antitumor agent in extraskeletal tissues. Therefore, we developed stealth liposomes encapsulating ZOL (LipoZOL) to increase extraskeletal drug availability. Compared to free ZOL, LipoZOL induced a stronger inhibition of growth of a range of different cancer cell lines in vitro. LipoZOL also caused significantly larger inhibition of tumor growth and increased the overall survival in murine models of human prostate cancer and multiple myeloma, in comparison with ZOL. Moreover, a strong inhibition of vasculogenetic events without evidence of necrosis in the tumor xenografts from prostate cancer was recorded after treatment with LipoZOL. We demonstrated both antitumor activity and tolerability of LipoZOL in preclinical animal models of both solid and hematopoietic malignancies, providing a rationale for early exploration of use of LipoZOL as a potential anticancer agent in cancer patients. FROM THE CLINICAL EDITOR: The short plasma half-life and rapid accumulation in bone limits the use of zoledronic acid as an antitumor agent in extraskeletal tissues. Therefore, stealth liposomes encapsulating ZOL (LipoZOL) have been developed to increase extraskeletal drug availability.

Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes / Marra, M; Salzano, Giuseppina; Leonetti, C; Tassone, P; Scarsella, M; Zappavigna, S; Calimeri, T; Franco, R; Liguori, G; Cigliana, G; Ascani, R; La Rotonda, Mi; Abbruzzese, A; Tagliaferri, P; Caraglia, M; DE ROSA, Giuseppe. - In: NANOMEDICINE. - ISSN 1549-9634. - 7:6(2011), pp. 955-964. [10.1016/j.nano.2011.03.004]

Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes

SALZANO, GIUSEPPINA;DE ROSA, GIUSEPPE
2011

Abstract

Zoledronic acid (ZOL) is a potent amino-bisphosphonate used for the treatment of bone metastases with recently reported antitumor activity. However, the short plasma half-life and rapid accumulation in bone limits the use of ZOL as an antitumor agent in extraskeletal tissues. Therefore, we developed stealth liposomes encapsulating ZOL (LipoZOL) to increase extraskeletal drug availability. Compared to free ZOL, LipoZOL induced a stronger inhibition of growth of a range of different cancer cell lines in vitro. LipoZOL also caused significantly larger inhibition of tumor growth and increased the overall survival in murine models of human prostate cancer and multiple myeloma, in comparison with ZOL. Moreover, a strong inhibition of vasculogenetic events without evidence of necrosis in the tumor xenografts from prostate cancer was recorded after treatment with LipoZOL. We demonstrated both antitumor activity and tolerability of LipoZOL in preclinical animal models of both solid and hematopoietic malignancies, providing a rationale for early exploration of use of LipoZOL as a potential anticancer agent in cancer patients. FROM THE CLINICAL EDITOR: The short plasma half-life and rapid accumulation in bone limits the use of zoledronic acid as an antitumor agent in extraskeletal tissues. Therefore, stealth liposomes encapsulating ZOL (LipoZOL) have been developed to increase extraskeletal drug availability.
2011
Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes / Marra, M; Salzano, Giuseppina; Leonetti, C; Tassone, P; Scarsella, M; Zappavigna, S; Calimeri, T; Franco, R; Liguori, G; Cigliana, G; Ascani, R; La Rotonda, Mi; Abbruzzese, A; Tagliaferri, P; Caraglia, M; DE ROSA, Giuseppe. - In: NANOMEDICINE. - ISSN 1549-9634. - 7:6(2011), pp. 955-964. [10.1016/j.nano.2011.03.004]
File in questo prodotto:
File Dimensione Formato  
2011_Marra et al Nanomed.pdf

non disponibili

Descrizione: Pubblicazione completa in formato pdf
Tipologia: Documento in Post-print
Licenza: Accesso privato/ristretto
Dimensione 930.93 kB
Formato Adobe PDF
930.93 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/423281
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 97
  • ???jsp.display-item.citation.isi??? 91
social impact